Custom Blend

Clinical References

Billon, C., et al. (2023). Synthetic ERRα/β Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology, 18(4), 765–771. DOI: 10.1021/acschembio.2c00720.
Billon, C., et al. (2023). A Synthetic ERβ Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics, 388(2), 232–240. DOI: 10.1124/jpet.123.100373.
Nguyen, T.X., et al. (2023). Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology, 193(12), 1986–1997. DOI: 10.1016/j.ajpath.2023.09.002.
Long, J., et al. (2022). REV-ERBα/β Activation Protects Neurons Against Parkinson’s Disease via Mitigation of NLRP3 Inflammasome. Journal of Neuroinflammation, 19(1), 133. DOI: 10.1186/s12974-022-02494-y.

*Based on preclinical and early mechanistic research—does not imply approved therapeutic use.

Hepatic Health: Reduced liver fat and improved liver function
Glucose Metabolism: Enhanced insulin sensitivity and glucose tolerance
Mitochondrial Function: Increased oxidative phosphorylation and cellular energy production
Inflammation: Suppression of chronic and neuroinflammatory signaling
Fat Loss & Adiposity: Increased fatty acid oxidation and reduced fat mass
Lipid Profiles: Lower triglycerides and improved cholesterol markers
Exercise Mimetic: Improved exercise capacity and metabolic efficiency

$100.00

Per Unit

In stock